283 related articles for article (PubMed ID: 17407651)
1. Oral antidiabetic agents in type 2 diabetes.
Levetan C
Curr Med Res Opin; 2007 Apr; 23(4):945-52. PubMed ID: 17407651
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes.
Pratley RE; Salsali A
Curr Med Res Opin; 2007 Apr; 23(4):919-31. PubMed ID: 17407649
[TBL] [Abstract][Full Text] [Related]
3. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
Krentz AJ; Bailey CJ
Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
[TBL] [Abstract][Full Text] [Related]
4. Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus.
Hermansen K; Mortensen LS
Drug Saf; 2007; 30(12):1127-42. PubMed ID: 18035865
[TBL] [Abstract][Full Text] [Related]
5. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.
Drucker DJ; Nauck MA
Lancet; 2006 Nov; 368(9548):1696-705. PubMed ID: 17098089
[TBL] [Abstract][Full Text] [Related]
6. [Evaluation of the association between the use of oral anti-hyperglycemic agents and hypoglycemia in Japan by data mining of the Japanese Adverse Drug Event Report (JADER) database].
Umetsu R; Nishibata Y; Abe J; Suzuki Y; Hara H; Nagasawa H; Kinosada Y; Nakamura M
Yakugaku Zasshi; 2014; 134(2):299-304. PubMed ID: 24492232
[TBL] [Abstract][Full Text] [Related]
7. Type 2 diabetes and oral antihyperglycemic drugs.
Mizuno CS; Chittiboyina AG; Kurtz TW; Pershadsingh HA; Avery MA
Curr Med Chem; 2008; 15(1):61-74. PubMed ID: 18220763
[TBL] [Abstract][Full Text] [Related]
8. Oral antidiabetic therapy in patients with heart disease. A cardiologic standpoint.
Fisman EZ; Tenenbaum A; Motro M; Adler Y
Herz; 2004 May; 29(3):290-8. PubMed ID: 15167955
[TBL] [Abstract][Full Text] [Related]
9. Rationale for dipeptidyl peptidase 4 inhibitors: a new class of oral agents for the treatment of type 2 diabetes mellitus.
Campbell RK
Ann Pharmacother; 2007 Jan; 41(1):51-60. PubMed ID: 17190843
[TBL] [Abstract][Full Text] [Related]
10. Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors.
Holst JJ
Expert Opin Emerg Drugs; 2004 May; 9(1):155-66. PubMed ID: 15155141
[TBL] [Abstract][Full Text] [Related]
11. A review of the effects of antihyperglycaemic agents on body weight: the potential of incretin targeted therapies.
Barnett A; Allsworth J; Jameson K; Mann R
Curr Med Res Opin; 2007 Jul; 23(7):1493-507. PubMed ID: 17559747
[TBL] [Abstract][Full Text] [Related]
12. Complementing insulin therapy to achieve glycemic control.
Barnett AH
Adv Ther; 2013 Jun; 30(6):557-76. PubMed ID: 23797471
[TBL] [Abstract][Full Text] [Related]
13. Pancreatic islet dysfunction in type 2 diabetes: a rational target for incretin-based therapies.
Meece J
Curr Med Res Opin; 2007 Apr; 23(4):933-44. PubMed ID: 17407650
[TBL] [Abstract][Full Text] [Related]
14. Weight effect of current and experimental drugs for diabetes mellitus: from promotion to alleviation of obesity.
Purnell JQ; Weyer C
Treat Endocrinol; 2003; 2(1):33-47. PubMed ID: 15871553
[TBL] [Abstract][Full Text] [Related]
15. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
Neumiller JJ
J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361
[TBL] [Abstract][Full Text] [Related]
16. [Exploring an optimal approach to the use of oral hypoglycemic agents based on CGM results: implications for combination therapy with oral hypoglycemic agents].
Mori Y
Nihon Rinsho; 2011 Aug; 69(8):1505-14. PubMed ID: 21838054
[TBL] [Abstract][Full Text] [Related]
17. Evaluating cardiovascular safety of novel therapeutic agents for the treatment of type 2 diabetes mellitus.
Azim S; Baker WL; White WB
Curr Cardiol Rep; 2014 Nov; 16(11):541. PubMed ID: 25303895
[TBL] [Abstract][Full Text] [Related]
18. [Current and future aspects of oral antidiabetic agents in type 2 diabetes].
Rybka J
Vnitr Lek; 2001 May; 47(5):285-90. PubMed ID: 11395869
[TBL] [Abstract][Full Text] [Related]
19. SGLT2 Inhibitors in Combination Therapy: From Mechanisms to Clinical Considerations in Type 2 Diabetes Management.
van Baar MJB; van Ruiten CC; Muskiet MHA; van Bloemendaal L; IJzerman RG; van Raalte DH
Diabetes Care; 2018 Aug; 41(8):1543-1556. PubMed ID: 30030256
[TBL] [Abstract][Full Text] [Related]
20. Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus.
Langley AK; Suffoletta TJ; Jennings HR
Pharmacotherapy; 2007 Aug; 27(8):1163-80. PubMed ID: 17655515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
